Launching into the Deep: Does the Pulmonary Microbiota Promote Chronic Lung Inflammation and Chronic Obstructive Pulmonary Disease Pathogenesis?

2016 ◽  
Vol 193 (9) ◽  
pp. 938-940 ◽  
Author(s):  
Marc A. Sze ◽  
Alison Morris
2014 ◽  
Vol 11 (Supplement 1) ◽  
pp. S76-S77 ◽  
Author(s):  
Alleluiah Rutebemberwa ◽  
Mark Stevens ◽  
Mario Perez ◽  
Lynelle Smith ◽  
Linda Sanders ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Hyojung Lee ◽  
Youngeun Kim ◽  
Hye Jin Kim ◽  
Soojin Park ◽  
Young Pyo Jang ◽  
...  

Chronic obstructive pulmonary disease (COPD), which is characterized by airway obstruction, leads to, as the two major forms of COPD, chronic bronchitis and emphysema. This study was conducted to evaluate the effects of herbal formula, PM014, in a murine model of COPD. Balb/c mice were treated once with each herb extract in PM014 or PM014 mixture via an oral injection. Lipopolysaccharide (LPS) or elastase/LPS were administrated to the mice to induce a disease that resembles COPD. PM014 treatment significantly attenuated the increased accumulation of immune cells in bronchoalveolar lavage fluid (BALF) compared to control mice. In addition, the TNF-αand IL-6 levels in BALF were decreased in the PM014 mice. Furthermore, histological analysis demonstrated that PM014 attenuated the hazardous effects of lung inflammation. These data suggest that PM014 exerts beneficial effects against forms of COPD such as lung inflammation.


2015 ◽  
Vol 1340 (1) ◽  
pp. 47-54 ◽  
Author(s):  
Giuseppe Valacchi ◽  
Emanuela Maioli ◽  
Claudia Sticozzi ◽  
Franco Cervellati ◽  
Alessandra Pecorelli ◽  
...  

2021 ◽  
Vol 72 (1) ◽  
pp. 119-134
Author(s):  
Michael C. Ferrera ◽  
Wassim W. Labaki ◽  
MeiLan K. Han

Chronic obstructive pulmonary disease (COPD) is a common respiratory disorder with significant morbidity and mortality. Despite its prevalence, COPD is underdiagnosed, and many patients do not receive a diagnosis until the disease is clinically advanced. Recent basic science and clinical research have focused on the early physiologic and pathobiologic changes in COPD with the hopes of improving diagnosis, providing targets for disease-modifying therapy, and identifying patients most likely to benefit from early intervention. Available treatments for COPD have grown substantially in the past 20 years with the introduction of new oral and inhaled medications as well as novel surgical and bronchoscopic procedures. This article summarizes some of the recent advances in our understanding of disease pathogenesis and treatment paradigms.


Sign in / Sign up

Export Citation Format

Share Document